BI Asset Management Fondsmaeglerselskab A S Grows Stake in Pfizer Inc. $PFE

Key Points

• BI Asset Management Fondsmaeglerselskab A S increased its Pfizer stake by 52.5% in the first quarter, adding 139,984 shares to bring its total to 406,477 shares valued at about $11.4 million.
• Pfizer’s CFO departure is the main near-term concern, but the company quickly named an interim finance chief and reaffirmed its 2026 guidance, signaling that operations and strategy remain on track.
• Pfizer recently beat quarterly expectations, reporting $0.75 EPS on $14.45 billion in revenue, while also paying a $0.43 quarterly dividend that implies a 6.8% annual yield.

BI Asset Management Fondsmaeglerselskab A S raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 52.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 406,477 shares of the biopharmaceutical company's stock after purchasing an additional 139,984 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Pfizer were worth $11,414,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in PFE. Vanguard Group Inc. increased its stake in shares of Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock valued at $13,479,520,000 after buying an additional 7,031,162 shares during the period. State Street Corp lifted its stake in Pfizer by 0.5% in the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company's stock worth $7,481,085,000 after acquiring an additional 1,357,756 shares during the period. Geode Capital Management LLC grew its holdings in Pfizer by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company's stock worth $3,235,642,000 after acquiring an additional 1,184,728 shares in the last quarter. Morgan Stanley increased its position in Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company's stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares during the period. Finally, Norges Bank purchased a new position in Pfizer during the 4th quarter valued at about $1,830,986,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reaffirmed its 2026 guidance and said its strategic outlook remains intact, which should help limit downside if investors focus on fundamentals rather than the management change. Pfizer stock slides following CFO exit, 2026 guidance reaffirmed
• Positive Sentiment: The company moved quickly to appoint an interim finance chief, suggesting Pfizer has a planned transition process in place rather than a broader disruption to operations. Pfizer Announces Chief Financial Officer Transition
• Neutral Sentiment: News coverage also noted that Pfizer’s recent move is part of a broader investor debate about the company’s near-term growth catalysts and pipeline execution, rather than a change to its core business outlook. Reuters coverage of CFO departure
• Negative Sentiment: The biggest overhang is the unexpected departure of the CFO, which can create uncertainty about financial discipline and near-term investor confidence, helping explain why PFE has been declining. Pfizer CFO to leave company for consumer goods role

Pfizer Trading Up 0.2%

NYSE PFE opened at $25.25 on Monday. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75. The company has a 50 day moving average price of $26.22 and a 200 day moving average price of $26.33. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm has a market cap of $143.94 billion, a PE ratio of 19.28 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer's revenue was up 5.4% compared to the same quarter last year. During the same period last year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer's dividend payout ratio (DPR) is presently 131.30%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. CICC Research started coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an "outperform" rating and a $33.00 price target for the company. UBS Group reissued a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. BMO Capital Markets restated an "outperform" rating and set a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. Wolfe Research reaffirmed an "underperform" rating and set a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Finally, Bank of America cut their price target on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $28.82.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.